FDA Approves Durvalumab for Limited-Stage Small Cell Lung Cancer By Ogkologos - January 17, 2025 837 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the ADRIATIC study Source RELATED ARTICLESMORE FROM AUTHOR Ovarian Reserve Better Indicator of Adjuvant Chemotherapy Benefit than Self-Reported Menopause Status, Age, or Other Hormone Levels Immune-Modulating SBRT Plus Anti-PD-L1 May Convert Immune-Cold ER-positive, HER2-negative EBC Into More Inflamed Tumours and Improve Response EMA Recommends Extension of Therapeutic Indications for Serplulimab MOST POPULAR Ranking of Molecular Alterations in HNSCC According to ESCAT Classification Provides... February 9, 2021 EMA Recommends Extension of Indications for Nivolumab and Ipilimumab September 25, 2020 Help Desk for Oncologists Treating People with a Rare Leukemia Pays... February 2, 2023 How I Balance Being Optimistic and Realistic During Advanced Lung Cancer December 29, 2021 Load more HOT NEWS EMA Recommends Extension of Indications for Ribociclib to Include Use in... Sparing the Hippocampus During PCI Better Preserves Cognitive Function in Patients... Exceptional Response Rates and Survival Among Patients with POLE/D1 Proofreading Deficient... EMA Recommends Granting a Conditional Marketing Authorisation for Nogapendekin alfa Inbakicept
